Mark Enyedy | President, Chief Executive Officer |
Renee Lentini | Chief Financial Officer (interim), Chief Accounting Officer |
Isabel Kalofonos | Chief Commercial Officer |
Anna Berkenblit | Chief Medical Officer |
Michael Vasconcelles | Executive Vice President, Research and Development |
Anabel Chan | Head of Investor Relations |
John Newman | Canaccord Genuity |
Michael Schmidt | Guggenheim |
Peter Lawson | Barclays |
Etzer Darout | BMO Capital Markets |
Boris Peaker | Cowen |
Andy Hsieh | William Blair |
Kelly Shi | Jefferies |
Swayampakula Ramakanth | HC Wainwright |
Asthika Goonewardene | Truist |
Joe Catanzaro | Piper Sandler |
Jonathan Chang | Leerink Partners |
Good morning and welcome to ImmunoGen’s second quarter 2023 financial and operating results conference call.
Today’s conference is being recorded.
At this time, I’d like to turn the call over to Anabel Chan, Head of Investor Relations. Please go ahead.
Good morning and thank you for joining today’s call.